logo

For the Inventor, By the Inventor

Taipei, Taiwan

Meng-Ju Lee

This inventor holds 6 USPTO granted patents. Top assignees: Center Laboratories, Inc., Other. Active years: 2018-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Meng-Ju Lee. Retrieved from https://idiyas.com/inventor/meng-ju-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 66.7

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal4 out of 6 
 
Center Laboratories, Inc.
 patents
silverMedal2 out of 834,513 
Other
 patents

Years Active: 2018-2021

Loading Chart...
6 patents (USPTO):Explore Patents
1. 10894023 - Oral pH independent dosage formulation for treating neurodegenerative disorders (2021-01-19),
2. 10639292 - Method of treating hyperglycemia (2020-05-05),
3. 10278943 - Method of treating hyperglycemia (2019-05-07),
4. 10144704 - Crystal forms of verapamil hydrochloride (2018-12-04),
5. 9980935 - Method of treating hyperglycemia (2018-05-29),
6. 9950995 - Crystal forms of verapamil hydrochloride (2018-04-24),

Title: Innovator Meng-Ju Lee: Contributions to Neurodegenerative Disorders and Hyperglycemia Treatments

Introduction

Meng-Ju Lee is a prominent inventor based in Taipei, Taiwan, who has made significant strides in the fields of pharmaceutical formulations and therapeutic methods. With a total of six patents to his name, Lee’s work showcases innovative approaches to treat critical health conditions such as neurodegenerative disorders and hyperglycemia.

Latest Patents

Among his latest contributions is a groundbreaking oral pH-independent dosage formulation designed for treating neurodegenerative disorders. This formulation uniquely combines both sustained-release and immediate-release drugs, featuring memantine as the sustained-release component, while the immediate-release components consist of donepezil and/or memantine. Remarkably, this formulation exhibits a pH-independent dissolution profile at a range from about 1.0 to about 7.0.

Another notable patent addresses methods for treating hyperglycemia, targeting disorders related to elevated blood sugar levels. This invention pertains to methods utilizing (R)-(+)-verapamil or its pharmaceutically acceptable salts, along with an α-glycosidase inhibitor, to manage conditions such as type I and II diabetes mellitus, gestational diabetes, and other related disorders.

Career Highlights

Throughout his career, Meng-Ju Lee has been affiliated with Center Laboratories, Inc., where he has applied his innovative thinking to pharmaceutical research and development. His contributions have shed light on effective treatment methodologies that are essential in modern medicine.

Collaborations

Lee has collaborated with distinguished colleagues, including Jui-Pao Hsu and Guang-Tzuu Shane, to advance his research initiatives. These collaborations have been pivotal in refining his inventions and expanding their potential applications in healthcare.

Conclusion

Meng-Ju Lee’s work exemplifies the spirit of innovation, particularly in addressing serious health challenges. With six patents to his name, his contributions continue to pave the way for new therapeutic solutions, benefiting patients worldwide. His commitment to research and development signifies the impact of dedicated inventors in advancing medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…